Results 81 to 90 of about 5,679 (109)
Analysis of MAP/PH1,PH2/1 queue with vacations and optional secondary services
semanticscholar +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
European Journal of Haematology, 2020
BACKGROUND AND AIMS Anagrelide is a drug effective in reducing platelet counts in Essential Thrombocythemia (ET) and Ph1-negative Myeloproliferative Neoplasms.
M. Mazzucconi +18 more
semanticscholar +1 more source
BACKGROUND AND AIMS Anagrelide is a drug effective in reducing platelet counts in Essential Thrombocythemia (ET) and Ph1-negative Myeloproliferative Neoplasms.
M. Mazzucconi +18 more
semanticscholar +1 more source
Rheological Properties and Microstructure of PH1 Stainless Steel Produced by Selective Laser Melting
Materials Science Forum, 2020The present study is focused on rheological properties of PH1 stainless steel, produced by selective laser melting (SLM), at temperatures of hot deformation, with the aim to investigate the dependence of strain resistance on temperature and strain degree.
S. Gladkovskii +4 more
semanticscholar +1 more source
bioRxiv
Diversification of the hexaploid (bread) wheat genetic pool using wild genetic resources relies on effective meiotic recombination (crossover) between wheat chromosomes and their counterparts from related species (homoeologues).
Camille Haquet +7 more
semanticscholar +1 more source
Diversification of the hexaploid (bread) wheat genetic pool using wild genetic resources relies on effective meiotic recombination (crossover) between wheat chromosomes and their counterparts from related species (homoeologues).
Camille Haquet +7 more
semanticscholar +1 more source
Blood, 2018
Prognosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1+ ALL) has been considerably improved since the beginning of the BCR-ABL1 tyrosine kinase inhibitors (TKI) era 20 years ago.
M. Couturier +7 more
semanticscholar +1 more source
Prognosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1+ ALL) has been considerably improved since the beginning of the BCR-ABL1 tyrosine kinase inhibitors (TKI) era 20 years ago.
M. Couturier +7 more
semanticscholar +1 more source

